Volgen
Marleen Keyaerts
Marleen Keyaerts
Geverifieerd e-mailadres voor vub.ac.be
Titel
Geciteerd door
Geciteerd door
Jaar
Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma
M Keyaerts, C Xavier, J Heemskerk, N Devoogdt, H Everaert, C Ackaert, ...
Journal of Nuclear Medicine 57 (1), 27-33, 2016
3832016
Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT
LOT Gainkam, L Huang, V Caveliers, M Keyaerts, S Hernot, I Vaneycken, ...
Journal of Nuclear Medicine 49 (5), 788-795, 2008
2712008
SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression
L Huang, LOT Gainkam, V Caveliers, C Vanhove, M Keyaerts, ...
Molecular Imaging and Biology 10 (3), 167-175, 2008
2362008
Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer
C Xavier, I Vaneycken, M D'huyvetter, J Heemskerk, M Keyaerts, C Vincke, ...
J Nucl Med 54 (5), 776-84, 2013
2252013
HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7
K Breckpot, D Escors, F Arce, L Lopes, K Karwacz, S Van Lint, M Keyaerts, ...
Journal of virology 84 (11), 5627-5636, 2010
1612010
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle
Y Dekempeneer, M Keyaerts, A Krasniqi, J Puttemans, S Muyldermans, ...
Expert opinion on biological therapy 16 (8), 1035-1047, 2016
1522016
Same-day imaging using small proteins: clinical experience and translational prospects in oncology
A Krasniqi, M D’Huyvetter, N Devoogdt, FY Frejd, J Sörensen, A Orlova, ...
Journal of Nuclear Medicine 59 (6), 885-891, 2018
1232018
Immunogenicity Risk Profile of Nanobodies
C Ackaert, N Smiejkowska, C Xavier, YGJ Sterckx, S Denies, B Stijlemans, ...
Frontiers in immunology 12, 578, 2021
1102021
Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers
K Broos, M Keyaerts, Q Lecocq, D Renmans, T Nguyen, D Escors, ...
Oncotarget 8 (26), 41932, 2017
1082017
Bioluminescence imaging: looking beyond the light
M Keyaerts, V Caveliers, T Lahoutte
Trends in molecular medicine 18 (3), 164-172, 2012
1082012
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
T Seremet, Y Jansen, S Planken, H Njimi, M Delaunoy, H El Housni, ...
Journal of translational medicine 17 (1), 1-13, 2019
1072019
Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D-luciferin: effect on intensity, time kinetics and repeatability of …
M Keyaerts, J Verschueren, TJ Bos, LO Tchouate-Gainkam, C Peleman, ...
European journal of nuclear medicine and molecular imaging 35 (5), 999-1007, 2008
1072008
The next-generation immune checkpoint LAG-3 and its therapeutic potential in oncology: Third time’sa charm
Q Lecocq, M Keyaerts, N Devoogdt, K Breckpot
International journal of molecular sciences 22 (1), 75, 2020
1052020
Noninvasive imaging of the PD-1: PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
K Broos, Q Lecocq, G Raes, N Devoogdt, M Keyaerts, K Breckpot
Theranostics 8 (13), 3559, 2018
1042018
Theranostics in immuno-oncology using nanobody derivatives
Q Lecocq, Y De Vlaeminck, H Hanssens, M D'Huyvetter, G Raes, ...
Theranostics 9 (25), 7772, 2019
922019
Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic Macrophages
C Xavier, A Blykers, D Laoui, E Bolli, I Vaneyken, J Bridoux, H Baudhuin, ...
Molecular imaging and biology 21, 898-906, 2019
762019
Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients
M D’Huyvetter, J De Vos, V Caveliers, I Vaneycken, J Heemskerk, ...
Journal of Nuclear Medicine 62 (8), 1097-1105, 2021
732021
Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy
LOT Gainkam, M Keyaerts, V Caveliers, N Devoogdt, C Vanhove, ...
Molecular Imaging and Biology 13 (5), 940-948, 2011
682011
Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent
K Broos, Q Lecocq, C Xavier, J Bridoux, TT Nguyen, J Corthals, ...
Cancers 11 (6), 872, 2019
592019
Inhibition of firefly luciferase by general anesthetics: effect on in vitro and in vivo bioluminescence imaging
M Keyaerts, I Remory, V Caveliers, K Breckpot, TJ Bos, J Poelaert, ...
PloS one 7 (1), e30061, 2012
562012
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20